A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice

This patient follow-up programme was designed to describe the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy in routine clinical practice in comparison with the already documented use of Symbicort as maintenance and reliever therapy in clinical therapies

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bronchial Asthma Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Aarschot, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this programme
signed and dated informed consent(ICF)
for patients under-age, signed and dated ICF form from both the patient and the patient's parent/legal guardian is required

Exclusion criteria

Involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start: 2007
Primary completion: 2010
Study completion: 2010
First posted: Jul 23, 2007
Registry last updated: Jan 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed